High Vista Strategies LLC Rigel Pharmaceuticals Inc Transaction History

High Vista Strategies LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.36 - $3.57 $51,304 - $77,608	-21,739 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$3.5 - $4.5 $29,774 - $38,281	8,507 Added 64.29%	21,739 $79,000
Q1 2021 May 17, 2021	SELL	$3.35 - $4.93 $31,185 - $45,893	-9,309 Reduced 41.3%	13,232 $45,000
Q4 2020 Feb 16, 2021	SELL	$2.35 - $3.74 $21,758 - $34,628	-9,259 Reduced 29.12%	22,541 $79,000
Q3 2020 Nov 16, 2020	SELL	$1.78 - $4.13 $14,952 - $34,692	-8,400 Reduced 20.9%	31,800 $76,000
Q2 2020 Aug 14, 2020	BUY	$1.41 - $2.05 $20,445 - $29,724	14,500 Added 56.42%	40,200 $74,000
Q1 2020 May 15, 2020	SELL	$1.27 - $3.0 $10,287 - $24,300	-8,100 Reduced 23.96%	25,700 $40,000
Q3 2019 Nov 14, 2019	BUY	$1.63 - $2.62 $55,094 - $88,556	33,800 New	33,800 $63,000

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $3.07B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of High Vista Strategies LLC, based on Form 13F filings with the SEC.

Stay updated on High Vista Strategies LLC with notifications on news.